Toxic multinodular goitre

From WikiProjectMed
(Redirected from Toxic nodular goitre)
Jump to navigation Jump to search
Toxic multinodular goiter
Other names: Toxic nodular goiter, Plummer's disease, multinodular toxic goiter, TMNG, MNTG
Causes of hyperthyroidism.png
Most common causes of hyperthyroidism by age.[1]
SpecialtyEndocrinology

Toxic multinodular goiter (TMNG), also known as multinodular toxic goiter (MNTG), is an active multinodular goiter associated with hyperthyroidism.

It is a common cause of hyperthyroidism[2][3] in which there is excess production of thyroid hormones from functionally autonomous thyroid nodules, which do not require stimulation from thyroid stimulating hormone (TSH).[4]

Toxic multinodular goiter is the second most common cause of hyperthyroidism (after Graves' disease) in the developed world, whereas iodine deficiency is the most common cause of hypothyroidism in developing-world countries where the population is iodine-deficient. (Decreased iodine leads to decreased thyroid hormone.) However, iodine deficiency can cause goiter (thyroid enlargement); within a goitre, nodules can develop. Risk factors for toxic multinodular goiter include individuals over 60 years of age and being female.[5]

Signs and symptoms

(Toxic) multinodular goitre

Symptoms of toxic multinodular goitre are similar to that of hyperthyroidism, including:[5]

Causes

Sequence of events:[6]

  1. Iodine deficiency leading to decreased T4 production.
  2. Induction of thyroid cell hyperplasia due to low levels of T4. This accounts for the multinodular goitre appearance.
  3. Increased replication predisposes to a risk of mutation in the TSH receptor.
  4. If the mutated TSH receptor is constitutively active, it would then become 'toxic' and produces excess T3/T4 leading to hyperthyroidism.

Diagnosis

Hyperthyroidism is diagnosed by evaluating symptoms and physical exam findings, and by conducting laboratory tests to confirm the presence of excess thyroid hormones. It is characterized by high levels of thyroid hormone in the blood along with a low level of thyroid-stimulating hormone (TSH). After diagnosing hyperthyroidism, a thyroid scan can be performed to determine the functionality of the thyroid gland using radioactive iodine. This scan can identify toxic nodules, which appear as a single area of overactivity, as well as toxic multinodular goiter, which presents with multiple areas of overactivity. In addition, a thyroid ultrasound can be conducted to better evaluate the presence of thyroid nodules.[7]

Treatments

Toxic multinodular goiter can be treated with antithyroid medications such as propylthiouracil or methimazole, radioactive iodine, or with surgery.[5] Another treatment option is injection of ethanol into the nodules.[8]

A Cochrane review compared treatments using recombinant human thyrotropin-aided radioactive iodine to radioactive iodine alone.[9] In this review it was found that the recombinant human thyrotropin-aided radioactive iodine appeared to lead to a greater of thyroid volume at the increased risk of hypothyroidism.[9] No conclusive data on changes in quality of life with either treatments were found.[9]

History

The usage of terminology for types of goiter has varied over the past century. Physicians and surgeons tend to differentiate among solitary-nodule goiter, multinodular goiter, and non-nodular goiter more thoroughly in recent decades than they formerly did. Thus some sources have described, or still describe, thyroid adenoma (toxic adenoma) as synonymous with toxic multinodular goiter,[10] but other sources differentiate those two as single-nodule disease versus multinodular disease (respectively) with pathogenesis that is likely differing in most cases (e.g., single neoplastic cell clone versus multifocal or diffuse molecular metabolic change). The medical eponyms "Plummer disease" (named after American physician Henry Stanley Plummer[11]) and "Parry disease" (named after English physician Caleb Hillier Parry) have been used to refer to toxic multinodular goiter, toxic adenoma, and toxic diffuse goiter (Graves' disease); the specific entity in each patient/case is not always clear retrospectively, especially in older literature. This is logical given that advanced medical imaging that can show what is happening at various places within a thyroid gland inside a living person (such as nuclear medicine imaging of radioiodine tracer uptake) was not available until after the 1940s.[citation needed]

References

  1. Carlé, Allan; Pedersen, Inge Bülow; Knudsen, Nils; Perrild, Hans; Ovesen, Lars; Rasmussen, Lone Banke; Laurberg, Peter (2011). "Epidemiology of subtypes of hyperthyroidism in Denmark: a population-based study". European Journal of Endocrinology. 164 (5): 801–809. doi:10.1530/EJE-10-1155. ISSN 0804-4643. PMID 21357288.
  2. de Rooij, A; Vandenbroucke, JP; Smit, JW; Stokkel, MP; Dekkers, OM (2009). "Clinical outcomes after estimated versus calculated activity of radioiodine for the treatment of hyperthyroidism: systematic review and meta-analysis". European Journal of Endocrinology. Bioscientifica. 161 (5): 771–777. doi:10.1530/EJE-09-0286. PMID 19671708.
  3. Krohn, K; Fuhrer, D; Bayer, Y; Eszlinger, M; Brauer, V; Neumann, S; Paschke, R (2005). "Molecular pathogenesis of euthyroid and toxic multinodular goiter". Endocrine Reviews. 26 (4): 504–524. doi:10.1210/er.2004-0005. PMID 15615818.
  4. Reid, JR; Wheeler, SF (2005). "Hyperthyroidism: diagnosis and treatment". American Family Physician. 72 (4): 623–630. PMID 16127951. Archived from the original on 2021-05-17. Retrieved 2023-04-24.
  5. 5.0 5.1 5.2 A.D.A.M. Medical Encyclopedia (2012). "Toxic nodular goiter". U.S. National Library of Medicine. Archived from the original on 29 May 2013. Retrieved 30 January 2013.
  6. Toxic Nodular Goiter at eMedicine
  7. "Toxic Nodule and Toxic Multinodular Goiter". American Thyroid Association. Archived from the original on 2023-02-15. Retrieved 2023-02-15.
  8. J. Larry Jameson; Leslie J. De Groot; David de Kretser; et al., eds. (2010). Endocrinology: adult and pediatric (6th ed.). Philadelphia: Saunders/Elsevier. p. Chapter 82. ISBN 9781416055839. Archived from the original on 2021-08-28. Retrieved 2023-04-24.
  9. 9.0 9.1 9.2 Huo, Yanlei; Xie, Jiawei; Chen, Suyun; Wang, Hui; Ma, Chao (2021-12-28). Cochrane Metabolic and Endocrine Disorders Group (ed.). "Recombinant human thyrotropin (rhTSH)-aided radioiodine treatment for non-toxic multinodular goitre". Cochrane Database of Systematic Reviews. 2021 (12). doi:10.1002/14651858.CD010622.pub2. PMC 8712889. PMID 34961921.
  10. Elsevier, Dorland's Illustrated Medical Dictionary, Elsevier, archived from the original on 2014-01-11, retrieved 2023-04-24.
  11. Plummer's disease eponymously named after Henry Stanley Plummer at Who Named It?

External links

Classification
External resources